Immix Biopharma Target Raised to $15 H.C. Wainwright raised Immix Biopharma's price target to $15 on Mar 27, 2026, signaling revised valuation assumptions; institutional investors should triangulate with SEC filings.

Immix Biopharma Target Raised to $15: H.C. Wainwright raised Immix Biopharma's price target to $15 on Mar 27, 2026, signaling revised valuation assumptions; institutional investors should triangulate with SEC… 👈 Read full analysis #ImmixBiopharma #Hcwainwright #PriceTarget #Investing #Biotech